2- Tuesday Pharmacy Practice News – 16th November

 1 – Evaluation of a Pharmacist-Led Intervention on Naloxone Co-Prescribing in Patients Receiving Chronic Opioid Therapy

• Although both the 2016 Centers for Disease Control and Preventon (CDC) guidelines and the 2020 Food and Drug Administration (FDA) safety announcement recommend naloxone co-prescribing to patients receiving chronic opioid therapy (COT) for non-cancer pain, the rate of naloxone co-prescription in this population remains low.
• The primary objective of this project was to determine whether a pharmacist intervention would lead to increased rates of naloxone co-prescribing among providers.
• A pharmacist-led intervention was found to increase the naloxone co-prescribing rate for COT patients. However, co-prescribing naloxone does not guarantee patient possession; only 56.4% of patients with a naloxone prescription appeared to have naloxone at home.
• Future studies should explore ways to increase naloxone possession rates.

Source: ACCP

2 – Research and Scholarly Methods: Pragmatic Clinical Trials

• Pragmatic clinical trials (PCTs) have received increased attention within health services and pharmacy practice research due to their ability to test interventions in the real world, with emphasis on implementation and scalability in diverse practice environments.
• The purpose of this article is to introduce the PCT research design to health service and pharmacy practice researchers, followed by considerations and recommendations for conducting successful PCT research.
• It is organized into three parts, including a definition of PCTs, the process of selecting a PCT design, and general considerations and recommendations of PCTs.

Source: ACCP

3 – Development and Application of Quality Measures of Clinical Pharmacist Services Provided in Inpatient/Acute Care Settings

• As health care transitions to value-based care, it is more critical than ever to emphasize and quantify the impact on patient outcomes made by inpatient/acute care pharmacists and pharmacist extenders as members of the interprofessional care team.
• Thus, the American College of Clinical Pharmacy (ACCP) took to task the development of quality measures that were broadly applicable to the diverse inpatient/acute care landscape and important for standardizing practice, measuring impact, contextualizing benefit within the health care landscape, and allowing benchmarking within and between institutions.
• A framework was established by the writing committee of this paper in order to develop quality measures in a methodical manner.
• The resulting process led the writing committee to devise 31 foundational quality measures to be used in efforts to champion the pharmacist’s role in achieving the quadruple aims in health care.
• Application and evaluation of quality measure performance as well as limitations and future implications of the measures are addressed to further highlight the evolving role of the inpatient/acute care pharmacist and pharmacist extender.

Source: ACCP

4- Tidutamab Shows Promise Treating Advanced Neuroendocrine Tumors

• Tidutamab (Xencor, Inc) showed a promising safety and tolerability profile in patients with advanced, well-differentiated neuroendocrine tumors (NETs) of pancreatic, gastrointestinal, lung, and undetermined origin in a phase 1 study.
• Tidutamab contains a somatostatin receptor 2 (SSTR2) binding domain and a T-cell binding domain (CD3).
• An XmAb bispecific Fc domain serves as a link between the antigen binding domains and aids in the extended circulating half-life, stability, and ease of manufacture for the drug, according to Xencor.
• By engaging with CD3, tidutamab activates T cells for targeted killing of SSTR2-expressing tumor cells, according to Xencor.

Source: Pharmacy Times

5 – FDA Approves Once-Daily Tablets for Attention-Deficit Hyperactivity Disorder

• The FDA has approved amphetamine (Dyanavel XR, Tris Pharma) extended-release once daily tablet, for the treatment of individuals 6 years of age or older with attention-deficit hyperactivity disorder (ADHD).
• Dyanavel XR oral suspension and now Dyanavel XR tablets provide a unique pharmacokinetic profile and a broad range of dosing options for patients needing an amphetamine for their ADHD
• In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension.
• The oral suspension demonstrated improvements of ADHD symptoms in children 6 to 12 years of age within an hour and lasted through 13 hours after once-daily dosing, according to Tris Pharma.
• In another study, the amphetamine oral suspension appeared to improve ADHD symptoms as soon as 30 minutes after dosing.

Source: Pharmacy Times

6 – The intersection of big data and epidemiology for epidemiologic research: The impact of the COVID-19 pandemic

• The coronavirus disease 2019 (COVID-19) pandemic has pushed infectious disease epidemiology and disease modeling to the forefront of the general public’s consciousness due to its profound impact, necessitating cultural changes steeped in focus on location and safety, such as universal masking, vaccination and social distancing.
• The COVID-19 pandemic has resulted in a rapidly increasing volume of available, digitized, global data fueling an increased pervasiveness of data-driven decision-making.
• Big data epidemiology facilitates pandemic response by providing data-driven insights by utilizing big data tools that differ from traditional methods.
• Aspects regarding ‘garbage in, garbage out’, such as insufficient data, inaccessibility of data, missing data, uncertainty in handling data and bias in analysis or common findings are addressable by combining techniques across disciplines.

Source: Oxford Academic

• Read more from FADIC Blog, with many articles with evidence based articles.
• Learn More Through FADIC® – Online Programs & Mini-Courses.
• Listen Now to FADIC Podcast focusing on varieties of pharmacist perspectives in specialties.
• Read More Now about FADIC Pharmacy Events to get more Experience.

Course Copyrights:

All Courses is meant for SINGLE user use only.
If more than one person acceced this course, they will be BLOCKED Forever.

Why FADIC 2020 Pharmacotherapy Daily News (FNN) ?

• It helps to keep up with the literature!
• Provide you with the Updated with the latest in your clinical practice. Wherever you are, and Whenever you need!
• Help you to share in the advance in clinical career. In addition to adding an impressive image to the pharmacists all-around!

Subscribe to FADIC 2021 Pharmacy Practice FNN E-News, for publication of:

Read & Download FNN Issue 8 of April 2020 FNN News